Sanguine Bio Accelerates Pace in Vaccine Race

Biotech: Blood samples are raw materials for virus research and development.

by Amy Stulick, Staff Reporter

As pharmaceutical labs race to develop a vaccine for COVID-19, biomaterial for researchers has become increasingly valuable. That works to the advantage of Sanguine Biosciences in Sherman Oaks, which provides blood, tissue, plasma, and other biologic material for R&D.

The company has grown 100 percent over the past six months, outlasting competitors such as Texas-based Examination Management Services Inc., which ceased operations on July 3.

Read the entire article here